Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Phase I Cetuximab and Concurrent Radio-chemotherapy
- Conditions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2011-07-19
- Lead Sponsor
- Maastricht Radiation Oncology
- Target Recruit Count
- 24
- Registration Number
- NCT00522886
- Locations
- 🇳🇱
Maastricht Radiation Oncology, MAASTRO clinic, Maastricht, Limburg, Netherlands
Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
- Conditions
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 150
- Registration Number
- NCT00517829
- Locations
- 🇺🇸
Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
🇺🇸Birmingham Hematology and Oncology, Birmingham, Alabama, United States
BIBW 2992 (Afatinib) in Head & Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 124
- Registration Number
- NCT00514943
- Locations
- 🇺🇸
1200.28.0024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸1200.28.0001 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸1200.28.0010 Boehringer Ingelheim Investigational Site, Stanford, California, United States
Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- ClinAssess
- Target Recruit Count
- 180
- Registration Number
- NCT00508664
- Locations
- 🇦🇹
Universitätsklinik für HNO, Graz, Austria
🇦🇹Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
🇦🇹Landeskrankenhaus Klagenfurt, Klagenfurt, Austria
Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial
- Conditions
- Interventions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Austrian South Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT00502463
- Locations
- 🇦🇹
LKH Feldkirch, Dept. of Radiooncology, Feldkirch, Austria
🇦🇹Medical University of Graz, Dept. of Radiooncology, Graz, Austria
🇦🇹LKH Leoben Dept. of Hemato-Oncology, Leoben, Austria
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT00501410
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
- Conditions
- Interventions
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00497497
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 40
- Registration Number
- NCT00492206
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸UPMC Cancer Center -Haymaker Rd., Monroeville, Pennsylvania, United States
🇺🇸UPMC Presbyterian -Radiation Oncology, Pittsburgh, Pennsylvania, United States
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 110
- Registration Number
- NCT00468169
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
- Conditions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2008-12-11
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 32
- Registration Number
- NCT00463073
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.